• Editas is using CRISPR/Cas9, a revolutionary genome editing tool, to first attempt to treat a cause of blindness by removing a genetic mutation, then move on to treating a blood condition by replacing a section of DNA with a new segment of it.
  • The startup raised $120 million in investment from funding led by Dr. Boris Nikolic, who created bng0 just to invest in Editas. "The company is at the forefront of genome editing -- one of the most exciting and important frontiers in science," said Nikolic.
  • Although CRISPR shows a lot of promise, it is still difficult to use safely and accurately even in laboratory settings and often causes undesired results. However, the investments from power players such as Bill Gates and Google show that there is confidence that it could have huge impacts on science and medicine.

Share This Article